This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 7-10, 2023 | In-Person + Digital
San Diego, CA, USAManchester Grand Hyatt San Diego

Marcus Schindler, PhD
Executive Vice President for Research & Early Development and CSO at Novo Nordisk A/S


Dr Schindler joined Novo Nordisk in January 2018 as Senior Vice President for External Innovation and Strategy. From March 2018 to 2021 he was Senior Vice President for Global Drug Discovery and in March 2021 Dr Schindler was appointed Executive Vice President Research & Early Development and Chief Scientific Officer. Prior to joining Novo Nordisk Dr Schindler was Vice President, head of Cardiovascular and Metabolic Diseases innovative Medicines (CVMD iMed) at AstraZeneca, Sweden. From 2009-2012 he was head of Research at (OSI) Prosidion, Oxford, UK. From 2000-2008 he worked in various leadership roles at Boehringer Ingelheim, Germany after having started his career with Glaxo Wellcome/GSK, UK in 1997. Dr Schindler holds a PhD from the University of Cambridge, UK. Dr Schindler is an Adjunct Professor of Pharmacology at the University of Gothenburg, Sweden.

Agenda Sessions

  • Driving Change for Future Generations